Summary
July 2008, Vol. 7, No. 4, Pages 377-387 , DOI 10.1517/14740338.7.4.377

The safety of cefepime in the treatment of infection

Lorenzo Drago PhD & Elena De Vecchi MSc
University of Milan, Laboratory of Clinical Microbiology, Department of Preclinical Science, LITA Vialba, Via GB Grassi 74, 20157 Milan, Italy +39 2 5031 9833; +39 2 5031 9651;
Author for correspondence



Background: Cefepime is a fourth-generation cephalosporin usually reserved for treating severe nosocomial pneumonia, as well as empirical treatment of febrile neutropenia, uncomplicated and complicated urinary tract infections, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. Objective: Since reports of neurotoxic effects and of an all-cause mortality higher with cefepime than with comparators have created some concerns regarding its safety, this paper reviews data available in the PubMed database up to December 2007 on cefepime safety. Methods: Literature data from PubMed obtained by combining cefepime and safety, or cefepime and clinical trials, were examined. Results/conclusions: Caution in the use of cefepime should be adopted until new evidence on cefepime safety is available.

Full Text | PDF (255 KB) | PDF Plus (239 KB)

Users who read this article also read:

A pan-HER approach for cancer therapy: background, current status and future development
Zhongdong Huang, Cathleen Brdlik, Pei Jin, H Michael Shepard
Expert Opinion on Biological Therapy, Jan 2009, Vol. 9, No. 1, Pages 97-110.
Summary | Full Text | PDF (1465 KB) | PDF Plus (1348 KB) | Add to Favorites | Related 
Exenatide and pancreatitis: an update
Steve C Bain, Jeffrey W Stephens
Expert Opinion on Drug Safety, Nov 2008, Vol. 7, No. 6, Pages 643-644.
Citation | Full Text | PDF (183 KB) | PDF Plus (152 KB) | Add to Favorites | Related 
The use and safety of doxycycline hyclate and other second-generation tetracyclines
Barry Sloan, Noah Scheinfeld
Expert Opinion on Drug Safety, Sep 2008, Vol. 7, No. 5, Pages 571-577.
Summary | Full Text | PDF (248 KB) | PDF Plus (217 KB) | Add to Favorites | Related 
Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome
Martin C Michel
Expert Opinion on Pharmacotherapy, Jul 2008, Vol. 9, No. 10, Pages 1787-1796.
Summary | Full Text | PDF (277 KB) | PDF Plus (258 KB) | Add to Favorites | Related 
Hypersensitivity reactions to cephalosporins
Esther Moreno, Eva Macías, Ignacio Dávila, Elena Laffond, Arturo Ruiz, Félix Lorente
Expert Opinion on Drug Safety, May 2008, Vol. 7, No. 3, Pages 295-304.
Summary | Full Text | PDF (459 KB) | PDF Plus (394 KB) | Add to Favorites | Related 
Imatinib mesilate for the treatment of gastrointestinal stromal tumour
Philippe A Cassier, Armelle Dufresne, Samia Arifi, Hiba El Sayadi, Intidar Labidi, Isabelle Ray-Coquard, Séverine Tabone, Pierre Méeus, Dominique Ranchère, Marie-Pierre Sunyach, Anne-Valérie Decouvelaere, Laurent Alberti, Jean-Yves Blay
Expert Opinion on Pharmacotherapy, May 2008, Vol. 9, No. 7, Pages 1211-1222.
Summary | Full Text | PDF (171 KB) | PDF Plus (276 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (255 KB)
View PDF Plus (239 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Lorenzo Drago
Elena De Vecchi
Keywords:
cefepime
drug safety
fourth-generation cephalosporins
severe infections